Nexalin Technology, Inc. (NXL )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol NXL
- Company Nexalin Technology, Inc.
- Price $0.58
- Changes Percentage 18.37
- Change 0.09
- Day Low $0.55
- Day High $0.65
- Year High $3.03
- Year Low $0.37
- Market Cap $10,818,125
- Price Avg 50 EMA (D) $0.65
- Price Avg 200 EMA (D) $0.99
- Exchange NASDAQ
- Volume 2,619,048
- Average Volume 277,155
- Open $0.59
- Previous Close $0.49
- EPS -0.65
- PE -0.89
- Earnings Announcement 2026-02-25 12:00:00
- Shares Outstanding $18,651,939
Company brief: NEXALIN TECHNOLOGY, INC. (NXL )
- Healthcare
- Medical - Devices
- Mr. Mark White
- https://www.nexalin.com
- US
- N/A
- 09-16-2022
- US65345B2016
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. The company's Nexalin device emits a patented frequency-based waveform, which stimulates a positive response from the mid-brain structures associated with various mental health disorders. It also engages in the development of Generation 2, a medical device that is in clinical trials for the treatment of substance abuse issues related to opiates, chronic pain, Alzheimer's disease, and dementia. The company was incorporated in 2021 and is headquartered in Houston, Texas.
NXL Corporation News
Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders
globenewswire.com -- Nexalin Participates in & Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders...